Literature DB >> 24795508

Lessons learned from studies of natural resistance in murine experimental autoimmune encephalomyelitis.

Harley Y Tse1, Jinzhu Li2, Xiaoqing Zhao3, Fei Chen3, Peggy P Ho4, Michael K Shaw5.   

Abstract

Experimental autoimmune encephalomyelitis (EAE) is a commonly-used animal model of the human demyelinating disease, multiple sclerosis (MS). Similar to MS, EAE is under genetic control in that certain mouse strains are susceptible to disease induction with myelin antigens, while other strains are resistant. In the past, major efforts studying EAE tended to focus on the mechanism of disease susceptibility pertaining to antigen specificities, disease progression and related cytokines. The basis of EAE resistance, on the other hand, had received relatively little attention. It is our contention that EAE resistance is a tightly regulated process and many lessons can be learned from studying its mechanisms. Initially, this laboratory showed that resistance to EAE induced by MBP in B6 mice and many other strains with different H-2 haplotypes could be reversed in an adoptive transfer system by challenging the recipients with MBP-CFA. The disease developed in these mice was very similar to that induced in EAE susceptible mouse strains without the antigenic challenge. This approach of reversing EAE resistance was confirmed by several other laboratories. It was also demonstrated definitively that EAE was mediated by the donor T cells and not by host T cells. Indeed, a "resistant" host environment did not affect the outcome of disease development. The antigenic challenge appeared to induce an anamnestic response in the donor T cells, as the antigen dose used could be as low as only 5µg per mouse. Significantly, the period between adoptive cell transfer and antigenic challenge could be as long as over one year, again indicating that the donor cells persisted in the host for a long period of time. Recently, it has been suggested that EAE resistance can be due to the activities of regulatory T cells (Tregs). Depletion of Tregs with anti-CD25 antibodies prior to immunization with PLP139-151 rendered 30% of resistant B10.S mice to develop EAE. These results were confirmed in SJL.B mice responding to MBP but not in B6 mice responding to the same antigen, suggesting that regulation might vary among EAE resistant mouse strains. In addition, it is noted that while B6 and SJL.B mice are resistant to EAE induction with MBP, these mice are susceptible to disease induction when immunized with MOG, suggesting that EAE susceptibility verses resistance is antigen dependent. This unique mouse model, coupled with advance technologies such as peptide/IA tetramers and microarrays, should provide a powerful tool for further elucidation of the basic mechanisms of EAE resistance.

Entities:  

Keywords:  H-2 haplotypes; autoimmune diseases; disease resistance; experimental autoimmune encephalomyetisis; multiple sclerosis; myelin basic protein; regulatory T cells

Year:  2012        PMID: 24795508      PMCID: PMC4005425     

Source DB:  PubMed          Journal:  Curr Trends Immunol        ISSN: 0972-4567


  66 in total

Review 1.  Susceptibility to experimental allergic encephalomyelitis in animal models of autoimmunity.

Authors:  F D Lublin
Journal:  Curr Opin Neurol Neurosurg       Date:  1992-04

Review 2.  The role of CD8(+) T cells in multiple sclerosis and its animal models.

Authors:  Joan Goverman; Antoine Perchellet; Eric S Huseby
Journal:  Curr Drug Targets Inflamm Allergy       Date:  2005-04

3.  The role of the antigen-presenting cell in Fas-mediated direct and bystander killing: potential in vivo function of Fas in experimental allergic encephalomyelitis.

Authors:  A R Thilenius; K A Sabelko-Downes; J H Russell
Journal:  J Immunol       Date:  1999-01-15       Impact factor: 5.422

4.  Autoimmune CD4+ T cell memory: lifelong persistence of encephalitogenic T cell clones in healthy immune repertoires.

Authors:  Naoto Kawakami; Francesca Odoardi; Tjalf Ziemssen; Monika Bradl; Thomas Ritter; Oliver Neuhaus; Hans Lassmann; Hartmut Wekerle; Alexander Flügel
Journal:  J Immunol       Date:  2005-07-01       Impact factor: 5.422

5.  Experimental allergic encephalomyelitis in susceptible and resistant strains of mice after adoptive transfer of T cells activated by antibodies to the T cell receptor complex.

Authors:  M L Zhao; J Q Xia; R B Fritz
Journal:  J Neuroimmunol       Date:  1992-09       Impact factor: 3.478

Review 6.  Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses.

Authors:  Shimon Sakaguchi
Journal:  Annu Rev Immunol       Date:  2004       Impact factor: 28.527

7.  Adoptive transfer of myelin basic protein-sensitized T cells produces chronic relapsing demyelinating disease in mice.

Authors:  F Mokhtarian; D E McFarlin; C S Raine
Journal:  Nature       Date:  1984 May 24-30       Impact factor: 49.962

8.  Experimental autoimmune encephalomyelitis-resistant mice have highly encephalitogenic myelin basic protein (MBP)-specific T cell clones that recognize a MBP peptide with high affinity for MHC class II.

Authors:  S Abromson-Leeman; J Alexander; R Bronson; J Carroll; S Southwood; M Dorf
Journal:  J Immunol       Date:  1995-01-01       Impact factor: 5.422

9.  Experimental allergic encephalomyelitis. T cell trafficking to the central nervous system in a resistant Thy-1 congenic mouse strain.

Authors:  D S Skundric; K Huston; M Shaw; H Y Tse; C S Raine
Journal:  Lab Invest       Date:  1994-11       Impact factor: 5.662

10.  Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation.

Authors:  M Asano; M Toda; N Sakaguchi; S Sakaguchi
Journal:  J Exp Med       Date:  1996-08-01       Impact factor: 14.307

View more
  1 in total

1.  Gene Therapy-Induced Antigen-Specific Tregs Inhibit Neuro-inflammation and Reverse Disease in a Mouse Model of Multiple Sclerosis.

Authors:  Geoffrey D Keeler; Sandeep Kumar; Brett Palaschak; Emily L Silverberg; David M Markusic; Noah T Jones; Brad E Hoffman
Journal:  Mol Ther       Date:  2017-09-21       Impact factor: 11.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.